A phase 2 trial randomised 120 Chinese adults with overweight or obesity and no diabetes to BGM0504 at three doses or placebo for 24 weeks. Mean weight fell by 10.7% on the 5 mg dose and by 18.3% on the 15 mg dose. Adverse events were most commonly gastrointestinal, drug-related events rose with dose from 53% to 93%, and none led to withdrawal.
Why it is interesting: Dose-ranging evidence for a further dual GLP-1/GIP agonist, against placebo rather than an existing drug.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.